Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Morgensztern

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine CarcinomasMartin Wermke, Valentina Gambardella, Yasutoshi Kuboki, et al.
The Annals of Thoracic Surgery|April 28, 2015
Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung CancerMatthew J Bott, Aalok P Patel, Traves D Crabtree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancerAalok P Patel, Traves D Crabtree, Jennifer M Bell, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 22, 2016
Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?Matthew J Bott, Aalok P Patel, Vivek Verma, et al.
JAMA Network Open|November 4, 2024
Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung CancerDwight Owen, Rotem Ben-Shachar, Josephine Feliciano, et al.
Cancer|January 17, 2020
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapyJared M Weiss, Nathan Pennell, Allison M Deal, et al.
Frontiers in Oncology|March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignanciesKian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine CarcinomasMartin Wermke, Valentina Gambardella, Yasutoshi Kuboki, et al.
The Annals of Thoracic Surgery|April 28, 2015
Role for Surgical Resection in the Multidisciplinary Treatment of Stage IIIB Non-Small Cell Lung CancerMatthew J Bott, Aalok P Patel, Traves D Crabtree, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2018
First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid TumorsJohn H Strickler, Colin D Weekes, John Nemunaitis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 12, 2014
National patterns of care and outcomes after combined modality therapy for stage IIIA non-small-cell lung cancerAalok P Patel, Traves D Crabtree, Jennifer M Bell, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 22, 2016
Patterns of care in hilar node-positive (N1) non-small cell lung cancer: A missed treatment opportunity?Matthew J Bott, Aalok P Patel, Vivek Verma, et al.
JAMA Network Open|November 4, 2024
Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung CancerDwight Owen, Rotem Ben-Shachar, Josephine Feliciano, et al.
Cancer|January 17, 2020
Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapyJared M Weiss, Nathan Pennell, Allison M Deal, et al.
Frontiers in Oncology|March 1, 2021
<i>nab</i>-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)Daniel Morgensztern, Manuel Cobo Dols, Santiago Ponce Aix, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
European Journal of Cancer (Oxford, England : 1990)|July 13, 2021
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignanciesKian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, et al.
Pageof 19